NEWS & Join Us

“The true sign of intelligence is not knowledge but imagination." — Albert Einstein

\

Tavotek Biotherapeutics Attends The 41st Annual J.P. Morgan Healthcare Conference

  • Author:
  • Origin:
  • Time of issue:2023-01-09
  • Views:2099

Tavotek Biotherapeutics Attends The 41st Annual J.P. Morgan Healthcare Conference

  • Author:
  • Origin:
  • Time of issue:2023-01-09
  • Views:2099

(LOWER GWYNEDD, Pennsylvania, January 9, 2023) Tavotek Biotherapeutics, a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs, attended the 41st annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis Hotel in San Francisco, California.

Dr. Mann Fung, MD, CEO of Tavotek, and Dr. Mark Chiu, PhD, CSO of Tavotek, met and connected with top industry leaders, innovative biotech startups, cutting-edge technology developers, and members of the investment community from the global stage.

“The biotech industry has been impacted by the pandemic and challenging economic conditions, but I believe there is optimism for continued innovation and progress in 2023. We look forward to collaboration opportunities with some promising companies that we have met with and will continue building relationships with potential partners and investors.”

About Tavotek

Tavotek Biotherapeutics is a multi-specific antibody drug company with the world's cutting-edge protein engineering technology, focusing on oncology and immunology diseases. The company's R&D is mainly built on three innovative breakthrough technology platforms, namely: TavoSelectTM, a bacteriophage biobank with AI assisted 3D selection; TavoPreciseTM, a sophisticated protein engineering platform that supports the development of bispecific and multi-specific antibodies, and TavoELITETM, an innovative synthetic biologic platform focusing on overcoming intracellular undruggable targets with particular focus on protein-protein interaction. With unique innovative R&D capabilities, biomarker-driven clinical development strategies, and efficient execution efficiency, Tavotek will provide treatment options with better efficacy, safety and convenience to advance medical care for patients.


Related News

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Biotherapeutics Announces Completion of Round B Financing with $35 Million
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Biotherapeutics Named Finalist for 2023 Annual Awards by Life Sciences Pennsylvania
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Launching First-In-Human Study of Two Assets In 2022
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Navrogen Inc. and Tavotek Biotherapeutics Announce Strategic Collaboration to Improve Therapeutic Efficacy of Antibody Pipeline Agents

727 Norristown Road, 3 Spring House Innovation Park Suite 101, Lower Gwynedd, Pennsylvania 19002

China. Suzhou. Suzhou Industrial Park. Unit 405, Building C2, No. 218, Xinghu Street

© 2023 Tavotek Biotherapeutics All rights reserved.   (267) 405-9426

© 2023 Tavotek Biotherapeutics All rights reserved.(267) 405-9426